Back to research
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Y. Ohe, F. Imamura, N. Nogami, I. Okamoto +9
AI Enhanced· 90%Source PDF
Not BES
AI summary
90% confidenceMES research in wastewater, bioelectrochemical. In the FLAURA trial Japanese subset, osimertinib significantly improved median PFS versus standard-o...
Generated by MESSAI extraction pipeline · review against source PDF
Extraction
Reported parameters
No values extracted from this paper yet.
No 3D model is mapped to this paper yet. Parameter ranges above still place reported values on the literature distribution.
Abstract
In the FLAURA trial Japanese subset, osimertinib significantly improved median PFS versus standard-of-care (gefitinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced or metastatic NSCLC.
Keywords
OsimertinibStandard of careOncologyInternal medicine
Identifiers
- Journal
- Japanese Journal of Clinical Oncology
- Year
- 2018